SRPT vs. CLS
Compare and contrast key facts about Sarepta Therapeutics, Inc. (SRPT) and Celestica Inc. (CLS).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: SRPT or CLS.
Correlation
The correlation between SRPT and CLS is 0.30, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
SRPT vs. CLS - Performance Comparison
Loading data...
Key characteristics
SRPT:
-0.98
CLS:
1.56
SRPT:
-1.70
CLS:
2.05
SRPT:
0.73
CLS:
1.29
SRPT:
-0.87
CLS:
2.24
SRPT:
-1.97
CLS:
5.56
SRPT:
35.38%
CLS:
21.78%
SRPT:
70.47%
CLS:
75.64%
SRPT:
-98.17%
CLS:
-96.93%
SRPT:
-77.59%
CLS:
-20.63%
Fundamentals
SRPT:
$3.93B
CLS:
$13.17B
SRPT:
-$2.64
CLS:
$3.58
SRPT:
159.25
CLS:
19.42
SRPT:
1.76
CLS:
1.31
SRPT:
3.44
CLS:
8.24
SRPT:
$2.23B
CLS:
$10.09B
SRPT:
$1.81B
CLS:
$1.07B
SRPT:
-$117.73M
CLS:
$724.86M
Returns By Period
In the year-to-date period, SRPT achieves a -67.06% return, which is significantly lower than CLS's 23.54% return. Over the past 10 years, SRPT has underperformed CLS with an annualized return of 4.33%, while CLS has yielded a comparatively higher 24.62% annualized return.
SRPT
-67.06%
-27.49%
-63.87%
-68.98%
-17.42%
-23.27%
4.33%
CLS
23.54%
41.49%
31.10%
116.62%
123.09%
78.40%
24.62%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
SRPT vs. CLS — Risk-Adjusted Performance Rank
SRPT
CLS
SRPT vs. CLS - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Sarepta Therapeutics, Inc. (SRPT) and Celestica Inc. (CLS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
SRPT vs. CLS - Dividend Comparison
Neither SRPT nor CLS has paid dividends to shareholders.
Drawdowns
SRPT vs. CLS - Drawdown Comparison
The maximum SRPT drawdown since its inception was -98.17%, roughly equal to the maximum CLS drawdown of -96.93%. Use the drawdown chart below to compare losses from any high point for SRPT and CLS. For additional features, visit the drawdowns tool.
Loading data...
Volatility
SRPT vs. CLS - Volatility Comparison
Sarepta Therapeutics, Inc. (SRPT) has a higher volatility of 40.38% compared to Celestica Inc. (CLS) at 16.61%. This indicates that SRPT's price experiences larger fluctuations and is considered to be riskier than CLS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
SRPT vs. CLS - Financials Comparison
This section allows you to compare key financial metrics between Sarepta Therapeutics, Inc. and Celestica Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
SRPT vs. CLS - Profitability Comparison
SRPT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Sarepta Therapeutics, Inc. reported a gross profit of 607.29M and revenue of 744.86M. Therefore, the gross margin over that period was 81.5%.
CLS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Celestica Inc. reported a gross profit of 273.90M and revenue of 2.65B. Therefore, the gross margin over that period was 10.3%.
SRPT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Sarepta Therapeutics, Inc. reported an operating income of -300.39M and revenue of 744.86M, resulting in an operating margin of -40.3%.
CLS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Celestica Inc. reported an operating income of 128.80M and revenue of 2.65B, resulting in an operating margin of 4.9%.
SRPT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Sarepta Therapeutics, Inc. reported a net income of -447.51M and revenue of 744.86M, resulting in a net margin of -60.1%.
CLS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Celestica Inc. reported a net income of 86.20M and revenue of 2.65B, resulting in a net margin of 3.3%.